TY - JOUR
T1 - Clinical implications of subclinical left ventricular dysfunction in heart failure with preserved ejection fraction
T2 - The PARAGON-HF study
AU - Minamisawa, Masatoshi
AU - Inciardi, Riccardo M.
AU - Claggett, Brian
AU - Cikes, Maja
AU - Liu, Li
AU - Prasad, Narayana
AU - Biering-Sørensen, Tor
AU - Lam, Carolyn S.P.
AU - Shah, Sanjiv J.
AU - Zile, Michael R.
AU - O'Meara, Eileen
AU - Redfield, Margaret M.
AU - McMurray, John J.V.
AU - Solomon, Scott D.
AU - Shah, Amil M.
N1 - Publisher Copyright:
© 2024 European Society of Cardiology.
PY - 2024/4
Y1 - 2024/4
N2 - Aims: Left ventricular (LV) subclinical impairment has been described in heart failure with preserved ejection fraction (HFpEF). We assessed the relationship between LV myocardial deformation by strain imaging and recurrent hospitalization for heart failure (HF) or cardiovascular death in a large international HFpEF population. Methods and results: We assessed two-dimensional speckle-tracking based global longitudinal strain (GLS) in 790 patients (mean age 74 ± 8 years, 54% female) with adequate image quality enrolled in the PARAGON-HF echocardiography study. We examined the relationship of GLS with total HF hospitalizations and cardiovascular death (the primary composite outcome) after accounting for clinical confounders. Approximately 47% of the population had evidence of LV subclinical dysfunction, defined as absolute GLS <16%. Impaired GLS was significantly associated with higher values of circulating baseline N-terminal pro-B-type-natriuretic peptide. After a median follow-up of 3.0 years, there were 407 total HF hospitalizations and cardiovascular deaths. After multivariable adjustment, worse GLS was associated with a greater risk for the primary composite outcome (adjusted hazard ratio per 1% decrease: 1.06; 95% confidence interval 1.02–1.11; p = 0.008). GLS did not modify the treatment effect of sacubitril/valsartan compared with valsartan for the composite outcome (p for interaction >0.1). Conclusions: In a large HFpEF population, impaired LV function was observed even among patients with preserved ejection fraction, and was associated with an increased risk of total HF hospitalizations or cardiovascular death, accounting for clinical confounders. These findings highlight the key role of subtle LV systolic impairment in the pathophysiology of HFpEF.
AB - Aims: Left ventricular (LV) subclinical impairment has been described in heart failure with preserved ejection fraction (HFpEF). We assessed the relationship between LV myocardial deformation by strain imaging and recurrent hospitalization for heart failure (HF) or cardiovascular death in a large international HFpEF population. Methods and results: We assessed two-dimensional speckle-tracking based global longitudinal strain (GLS) in 790 patients (mean age 74 ± 8 years, 54% female) with adequate image quality enrolled in the PARAGON-HF echocardiography study. We examined the relationship of GLS with total HF hospitalizations and cardiovascular death (the primary composite outcome) after accounting for clinical confounders. Approximately 47% of the population had evidence of LV subclinical dysfunction, defined as absolute GLS <16%. Impaired GLS was significantly associated with higher values of circulating baseline N-terminal pro-B-type-natriuretic peptide. After a median follow-up of 3.0 years, there were 407 total HF hospitalizations and cardiovascular deaths. After multivariable adjustment, worse GLS was associated with a greater risk for the primary composite outcome (adjusted hazard ratio per 1% decrease: 1.06; 95% confidence interval 1.02–1.11; p = 0.008). GLS did not modify the treatment effect of sacubitril/valsartan compared with valsartan for the composite outcome (p for interaction >0.1). Conclusions: In a large HFpEF population, impaired LV function was observed even among patients with preserved ejection fraction, and was associated with an increased risk of total HF hospitalizations or cardiovascular death, accounting for clinical confounders. These findings highlight the key role of subtle LV systolic impairment in the pathophysiology of HFpEF.
KW - Aged
KW - Aged, 80 and over
KW - Aminobutyrates/therapeutic use
KW - Angiotensin Receptor Antagonists/therapeutic use
KW - Biphenyl Compounds
KW - Drug Combinations
KW - Echocardiography/methods
KW - Female
KW - Heart Failure/physiopathology
KW - Heart Ventricles/physiopathology
KW - Hospitalization/statistics & numerical data
KW - Humans
KW - Male
KW - Natriuretic Peptide, Brain/blood
KW - Peptide Fragments/blood
KW - Prognosis
KW - Stroke Volume/physiology
KW - Tetrazoles/therapeutic use
KW - Valsartan/therapeutic use
KW - Ventricular Dysfunction, Left/physiopathology
UR - http://www.scopus.com/inward/record.url?scp=85186184637&partnerID=8YFLogxK
U2 - 10.1002/ejhf.3167
DO - 10.1002/ejhf.3167
M3 - Journal article
C2 - 38369856
AN - SCOPUS:85186184637
SN - 1388-9842
VL - 26
SP - 871
EP - 881
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
IS - 4
ER -